Hardeep Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hardeep Kaur has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Sung
Department of Biochemistry and Structural Biology and Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, USA
4 shared publications - Cody M. Rogers
Department of Biochemistry and Structural Biology and Greehey Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, USA
3 shared publications - David S. Libich
Department of Biochemistry and Structural Biology, and Greehey Children’s Cancer Research Institute, The University of Texas at San Antonio Health Science Center, San Antonio, USA
3 shared publications - Weixing Zhao
Department of Biochemistry and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, USA
3 shared publications - Youngho Kwon
Department of Biochemistry and Structural Biology, the Center for Innovative Drug Discovery, and the Greehey Children’s Cancer Research Institute, the University of Texas Health Science Center San Antonio , San Antonio, TX 78229
3 shared publications Aida Badamchi Shabestari
Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA
2 shared publications
Latest Publications
- 18 September 2026
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- p. 1-14
Mechanisms and disease relevance of DNA break repair pathway choice
Understanding what drives the choice between homologous recombination (HR) and non-homologous end joining (NHEJ) as the DNA double-strand break (DSB) repair pathway can help to elucidate mechanisms of genome repair and acquired drug resistance in cancer cells. This choice is intimately linked with a highly regulated process of DNA end resection, mediated by several nuclease entities. Concerted efforts by many laboratories have identified several factors involved in DNA end resection, but we are only beginning to appreciate the mechanisms that underpin DSB repair pathway choice. In this Review, we highlight how DSB repair factors, DSB repair regulators and chromatin modifications determine whether HR or NHEJ is engaged as the repair pathway, with a focus on the antagonistic roles of the tumour suppressor complex BRCA1–BARD1 and the 53BP1 axis in repair pathway choice. How RNA–DNA hybrids affect HR execution and how they are processed by helicases and HR factors is also discussed. Moreover, we describe how dysfunction in repair pathway choice affects tumorigenesis and drives chemotherapeutic resistance.
- 18 September 2026
- Published by Springer Nature in Nature Reviews Molecular Cell Biology
- p. 1-14
Mechanisms and disease relevance of DNA break repair pathway choice
Understanding what drives the choice between homologous recombination (HR) and non-homologous end joining (NHEJ) as the DNA double-strand break (DSB) repair pathway can help to elucidate mechanisms of genome repair and acquired drug resistance in cancer cells. This choice is intimately linked with a highly regulated process of DNA end resection, mediated by several nuclease entities. Concerted efforts by many laboratories have identified several factors involved in DNA end resection, but we are only beginning to appreciate the mechanisms that underpin DSB repair pathway choice. In this Review, we highlight how DSB repair factors, DSB repair regulators and chromatin modifications determine whether HR or NHEJ is engaged as the repair pathway, with a focus on the antagonistic roles of the tumour suppressor complex BRCA1–BARD1 and the 53BP1 axis in repair pathway choice. How RNA–DNA hybrids affect HR execution and how they are processed by helicases and HR factors is also discussed. Moreover, we describe how dysfunction in repair pathway choice affects tumorigenesis and drives chemotherapeutic resistance.
- Open Access
BRCA1 promotes homologous recombination through separable DNA and RAD51 binding activities within its disordered region
The breast and ovarian tumor suppressor BRCA1 heterodimerizes with BARD1 to promote DNA double-strand break repair by homologous recombination (HR) and to protect stressed DNA replication forks against nuclease attack. The large, intrinsically disordered central region of BRCA1 harbors binding sites for DNA and multiple repair factors, but its lack of stable structure has hindered mechanistic dissection of these activities. Using biochemical mapping and NMR spectroscopy, we delineate the DNA binding and RAD51 interaction interfaces within this region and construct separation-of-function mutants that selectively ablate each activity. Both DNA binding and RAD51 interaction are required for BRCA1-BARD1 to promote RAD51-mediated DNA strand invasion, and DNA binding also contributes to BLM-DNA2 end resection. These findings provide mechanistic insights into how individual ligand binding activities within BRCA1 contribute to genome maintenance.
Open AccessBRCA1 promotes homologous recombination through separable DNA and RAD51 binding activities within its disordered region
The breast and ovarian tumor suppressor BRCA1 heterodimerizes with BARD1 to promote DNA double-strand break repair by homologous recombination (HR) and to protect stressed DNA replication forks against nuclease attack. The large, intrinsically disordered central region of BRCA1 harbors binding sites for DNA and multiple repair factors, but its lack of stable structure has hindered mechanistic dissection of these activities. Using biochemical mapping and NMR spectroscopy, we delineate the DNA binding and RAD51 interaction interfaces within this region and construct separation-of-function mutants that selectively ablate each activity. Both DNA binding and RAD51 interaction are required for BRCA1-BARD1 to promote RAD51-mediated DNA strand invasion, and DNA binding also contributes to BLM-DNA2 end resection. These findings provide mechanistic insights into how individual ligand binding activities within BRCA1 contribute to genome maintenance.
- Open Access
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Multifaceted roles of PDS5B in RAD51-dependent homology-directed DNA repair and replication fork protection
PDS5B (Precocious Dissociation of Sisters 5B) functions in sister chromatid cohesion and genome organization. Interestingly, PDS5B also associates with RAD51, the recombinase required for DNA damage repair by homologous recombination (HR) and the preservation of stressed DNA replication forks against nucleolytic attrition. We show that PDS5B binds dsDNA preferentially over ssDNA and that it enhances RAD51-mediated DNA strand exchange via the capture of dsDNA. PDS5B also acts synergistically with BRCA2-DSS1 to help overcome the interference of RPA in DNA strand exchange and works in conjunction with RAD51 to protect dsDNA against digestion by MRE11-RAD50-NBS1. DNA binding activity resides within the disordered C-terminal region of PDS5B, and testing of a DNA binding mutant provides evidence that this PDS5B attribute underpins protein functions in vitro and in HR and replication fork protection in cells. Our findings thus reveal distinct functions of PDS5B in genome repair and maintenance.
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMultifaceted roles of PDS5B in RAD51-dependent homology-directed DNA repair and replication fork protection
PDS5B (Precocious Dissociation of Sisters 5B) functions in sister chromatid cohesion and genome organization. Interestingly, PDS5B also associates with RAD51, the recombinase required for DNA damage repair by homologous recombination (HR) and the preservation of stressed DNA replication forks against nucleolytic attrition. We show that PDS5B binds dsDNA preferentially over ssDNA and that it enhances RAD51-mediated DNA strand exchange via the capture of dsDNA. PDS5B also acts synergistically with BRCA2-DSS1 to help overcome the interference of RPA in DNA strand exchange and works in conjunction with RAD51 to protect dsDNA against digestion by MRE11-RAD50-NBS1. DNA binding activity resides within the disordered C-terminal region of PDS5B, and testing of a DNA binding mutant provides evidence that this PDS5B attribute underpins protein functions in vitro and in HR and replication fork protection in cells. Our findings thus reveal distinct functions of PDS5B in genome repair and maintenance.
- 22 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6749) , 881-888
CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade
Antagonistic activities of the 53BP1 axis and the tumor suppressor BRCA1-BARD1 determine whether DNA double-strand breaks (DSBs) are repaired by end joining or homologous recombination. We show that the CTC1-STN1-TEN1 (CST) complex, a central 53BP1 axis component, suppresses DNA end resection by EXO1 and the BLM-DNA2 helicase-nuclease complex but acts by distinct mechanisms in restricting these entities. Whereas BRCA1-BARD1 alleviates the CST-imposed EXO1 blockade, it has little effect on BLM-DNA2 restriction. CST mutants impaired for DNA binding or BLM–EXO1 interaction exhibit a hyper-resection phenotype and render BRCA1-deficient cells resistant to poly(ADP–ribose) polymerase (PARP) inhibitors. Our findings mechanistically define the crucial role of CST in DNA DSB repair pathway choice and have implications for understanding cancer therapy resistance stemming from dysfunction of the 53BP1 axis.
- 22 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6749) , 881-888
CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade
Antagonistic activities of the 53BP1 axis and the tumor suppressor BRCA1-BARD1 determine whether DNA double-strand breaks (DSBs) are repaired by end joining or homologous recombination. We show that the CTC1-STN1-TEN1 (CST) complex, a central 53BP1 axis component, suppresses DNA end resection by EXO1 and the BLM-DNA2 helicase-nuclease complex but acts by distinct mechanisms in restricting these entities. Whereas BRCA1-BARD1 alleviates the CST-imposed EXO1 blockade, it has little effect on BLM-DNA2 restriction. CST mutants impaired for DNA binding or BLM–EXO1 interaction exhibit a hyper-resection phenotype and render BRCA1-deficient cells resistant to poly(ADP–ribose) polymerase (PARP) inhibitors. Our findings mechanistically define the crucial role of CST in DNA DSB repair pathway choice and have implications for understanding cancer therapy resistance stemming from dysfunction of the 53BP1 axis.